The two companies will work on a number of studies to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large scale vector production.
CDMO Matica Biotechnology, which specializes in the clinical and commercial production of gene and cell therapies, will contribute its viral vector production experience and work alongside Sartorius’ technology.
Michael Stewart, chief technology officer, Matica Bio said: "The generation of in-line real-time process data is one of the most significant obstacles to achieving consistent, high-producing viral vector titers during development that can be translatable to large scale production. In many respects, what is going on inside a bioreactor or within downstream operations is still a black box to us.
"Matica Bio's development, manufacturing and quality teams have decades of viral vector production experience. Applying our expertise together with Sartorius' industry-leading single-use and PAT technologies will allow us to provide more robust, consistent results for our clients, guiding informed decision-making throughout the manufacturing process and accelerating the overall development timeline to the clinic and market."
The two companies say they are together dedicated to solving the challenges of large-scale cell culture and viral vector production, improving manufacturability and reducing the costs of novel cell and gene therapies, oncolytic vectors and vaccines.
